Moderna announces omicron-containing bivalent booster candidate mrna-1273.214 demonstrates superior antibody response against omicron

Data show significantly higher geometric mean titer ratios, meeting prespecified endpoints for superiority against omicron variant mrna-1273.214 exhibited an 8-fold boost in neutralizing geometric mean titers against omicron among baseline seronegative participants safety and tolerability profile for mrna-1273.214 is consistent with prior booster dose of mrna-1273 regulatory submission planned for coming weeks to enable use of mrna-1273.214 for fall booster conference call to be held today at 8:00 am et cambridge, ma / accesswire / june 8, 2022 / moderna, inc., (nasdaq:mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced new clinical data on its omicron-containing bivalent covid booster candidate, mrna-1273.214, containing mrna-1273 (spikevax) and a vaccine candidate targeting the omicron variant of concern. a 50 Μg booster dose of mrna-1273.214 met all pre-specified endpoints including superior neutralizing antibody response (geometric mean ratio) against the omicron variant one month after administration when compared to the original mrna-1273 vaccine.the booster dose of mrna-1273.214 was generally well-tolerated, with side effects comparable to a booster dose of mrna-1273 at the 50 Μg dose level.
MRNA Ratings Summary
MRNA Quant Ranking